"The effect of herbal supplements on neurotransmitters in the formation of dementia"

"Evaluation of the possible effect of berberine supplementation on changes in serum levels of glutamate-dopamin-serotonin and GABA neurotransmitters in dementia patients"

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211012052739N1

Enrollment

105

Registered

2021-11-08

Start date

2021-10-25

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia. Dementia in other diseases classified elsewhere without behavioral disturbance

Interventions

Intervention 1: Intervention group: Berberine is a herbal supplement, in the form of a capsule, with a dose of 300 mg, given three times a day for two months for patients with dementia. Medication sho

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion age (at least 65 years) Complete DSM_IV diagnostic questionnaires by a partner specialist Proof of dementia by CT scan, MRI The same conditions as the severity of the disease

Exclusion criteria

Exclusion criteria: Having similar neurological disorders Alcohol consumption history in the past year History of gastrointestinal diseases

Design outcomes

Primary

Measure	Time frame
GABA amino butyric acid. Timepoint: At the beginning of the study (before the intervention) and 60 days after starting the drug. Method of measurement: High-performance liquid chromatography.;Dopamine. Timepoint: At the beginning of the study (before the intervention) and 60 days after starting the drug. Method of measurement: High-performance liquid chromatography.;Serotonin. Timepoint: At the beginning of the study (before the intervention) and 60 days after starting the drug. Method of measurement: High-performance liquid chromatography.;Glutamate. Timepoint: At the beginning of the study (before the intervention) and 60 days after starting the drug. Method of measurement: High-performance liquid chromatography.	—

Measure

Time frame

GABA amino butyric acid. Timepoint: At the beginning of the study (before the intervention) and 60 days after starting the drug. Method of measurement: High-performance liquid chromatography.;Dopamine. Timepoint: At the beginning of the study (before the intervention) and 60 days after starting the drug. Method of measurement: High-performance liquid chromatography.;Serotonin. Timepoint: At the beginning of the study (before the intervention) and 60 days after starting the drug. Method of measurement: High-performance liquid chromatography.;Glutamate. Timepoint: At the beginning of the study (before the intervention) and 60 days after starting the drug. Method of measurement: High-performance liquid chromatography.

—

Secondary

Measure	Time frame
Improving patient memory and slowing the progression of patient perceptual defects. Timepoint: 60 days after starting Berberine supplementation. Method of measurement: Questionnaire for scores of clinical change assessment (CGI) and psychiatric grading criteria (BpRS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamidreza Rahmani

Fasa University of Medical Sciences

h.rahmani@fums.ac.ir+98 71 5335 0994

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026